Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Type2 Diabetes Mellitus
Interventions: Bexagliflozin tablets, 20 mg, Bexagliflozin tablets, placebo; Drug
Lead sponsor: Theracos; Industry
Eligibility: 20 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 26
States / cities: Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 21 more

Conditions: Anxiety, Stress
Interventions: Placebo Control Form 1, Calm Active Study Product 1.1 Usage, Placebo Control 6.1, Calm Active Study Product 6.1 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 502 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Dry Eye Syndrome
Interventions: SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution; Drug
Lead sponsor: Mitotech, SA; Industry
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Sun City West, Arizona • Andover, Massachusetts • San Antonio, Texas + 1 more

Conditions: Diabetic Macular Edema
Interventions: RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg); Genetic · Biological
Lead sponsor: Sierra Eye Associates; Other
Eligibility: 25 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Congenital Ichthyosis
Interventions: PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%; Drug
Lead sponsor: Patagonia Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more

Conditions: Influenza, Human
Interventions: Investigational aQIVc, licensed QIVr, licensed aQIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years and older
Enrollment: 7,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 51
States / cities: Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more

Conditions: Postoperative Pain
Interventions: patient-controlled epidural analgesia (PCEA), patient-controlled intravenous analgesia (PCA); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic; AUD
Interventions: Brief alcohol counseling, Group and Individual Therapy Sessions; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: Neridronic acid 100 mg, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 41
States / cities: Cottonwood, Arizona • Tempe, Arizona • Tucson, Arizona + 34 more

Conditions: Preterm Pregnancy, Labor Induction
Interventions: Early Amniotomy, Late Amniotomy; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Smoking Cessation
Interventions: CP-526,555 (varenicline); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 7
States / cities: Los Angeles, California • Farmington, Connecticut • Minneapolis, Minnesota + 4 more

Conditions: FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
Interventions: Placebo, CCX140-B; Other · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more

Conditions: Recurrent Prostate Cancer
Interventions: MGE, Placebo, ADT; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Salisbury, North Carolina • Winston-Salem, North Carolina

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo; Drug
Lead sponsor: Zydus Lifesciences Limited; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more

Conditions: Coronary Disease, Heart Valve Diseases
Interventions: CTI-01 (ethyl pyruvate); Drug
Lead sponsor: Critical Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Laguna Hills, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: Lymphocytic Colitis, Diarrhea
Interventions: Placebo, Budesonide; Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Celiac Disease
Interventions: larazotide acetate, placebo; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Orange, California • San Francisco, California • Torrington, Connecticut + 17 more

Conditions: Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
Interventions: Veliparib (ABT-888), Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Scottsdale, Arizona • San Antonio, Texas

Conditions: Overweight, Obesity
Interventions: 500 mL/day of a beverage providing approximately 625 mg catechins, Control beverage matched for energy and caffeine content; Dietary Supplement · Other
Lead sponsor: Provident Clinical Research; Other
Eligibility: 21 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: St. Petersburg, Florida • Bloomington, Indiana

Conditions: Graft Rejection
Interventions: Placebo, C1 Esterase Inhibitor (Human); Biological
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more

Conditions: Major Depressive Disorder, Bipolar Disorder, Schizophrenia
Interventions: Taking Action; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postoperative Pain
Interventions: Pregabalin, Acetaminophen, Placebo 1, Placebo 2; Drug · Other
Lead sponsor: Nevakar, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Pasadena, California • Bellaire, Texas

Conditions: Type I Hypersensitivity
Interventions: Grass MATA MPL, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 1,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 65
States / cities: Colorado Springs, Colorado • Denver, Colorado • Englewood, Colorado + 58 more

Conditions: Crohn's Disease
Interventions: AMG 139; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Berlin, New Jersey • Stony Brook, New York • Oklahoma City, Oklahoma + 1 more

Search by objective public record fields.

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Radicle Calm 24: A Study of Health and Wellness Products on Feelings of Anxiety and Related Health Outcomes

Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome

Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Patient-Controlled Epidural Analgesia (PCEA) for Patients Who Have Had Major Open Gynecologic Surgery

Hepatitis C Alcohol Reduction Treatment

Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

Preterm Induction of Labor Timing of Amniotomy: A Randomized Controlled Trial

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

A Study of CCX140-B in Subjects With FSGS

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Taking Action for College Students

A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

Efficacy and Safety/Tolerability of Grass MATA MPL

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects